BAT Hosts Successful CORESTA Global Tobacco Science Conference in Edinburgh

Oct.18.2024
BAT Hosts Successful CORESTA Global Tobacco Science Conference in Edinburgh
BAT successfully hosted the CORESTA global tobacco science conference in Edinburgh, focusing on harm reduction and public health opportunities.

On October 17, British American Tobacco (BAT) announced on their official website that the CORESTA Global Congress on Tobacco and Related Products Science was successfully held at the Edinburgh International Conference Center from October 13th to 17th. The event was hosted by BAT, and it brought together over 500 representatives from more than 30 countries, including businesses, research institutions, laboratories, associations, and regulatory bodies. The participants gathered to discuss the prospects of harm reduction in tobacco.


The conference, themed "Advancing Tobacco Harm Reduction through Scientific Collaboration," focused on ways to create smoke-free alternatives for billions of tobacco users. It not only facilitated international dialogue on scientific research related to tobacco and nicotine but also showcased research findings and discoveries from CORESTA members, providing crucial support for the transition from combustible tobacco to smoke-free alternatives.


During the opening ceremony, Danni Tower, Head of Scientific and Regulatory Affairs at the company, gave a keynote speech emphasizing the progress of BAT in advancing tobacco harm reduction agenda. She mentioned that scientific collaboration is crucial in expanding public awareness and acceptance of tobacco harm reduction, and highlighted BAT's commitment to sharing and exchanging world-class scientific research.


The CORESTA conference highlighted the importance of global scientific collaboration to maximize public health opportunities for tobacco harm reduction. We are proud to host such an important event and believe that if all stakeholders recognize the potential for tobacco harm reduction, positive changes could occur globally.


In order to achieve this goal, as discussed this week, there is a need for more open dialogue in the fields of science and regulation. Therefore, we have recently launched Omni™- offering thoughtful ideas for a smoke-free world- which is an open, evidence-based platform based on leading scientific research.


Other keynote speakers at the conference include global health advocate Derek Yach, who spoke on the topic of "New Generation Products Require New Generation Science and Regulation.


The speech at the CORESTA conference showcased the scientific advancements being made using new methods to accelerate harm reduction in tobacco. These advancements ranged from the application of genomics in agricultural science to the development of biomarkers in research, as well as the use of artificial intelligence tools to enhance our understanding of the reasons and effects of interventions. All public health agencies, including the World Health Organization (WHO), should collaborate with CORESTA scientists to expedite change.


BAT stated that the CORESTA conference is just another example of its commitment to promoting public health interests by reducing the harm caused by tobacco globally. The company continues to invest in the development of new smoke-free tobacco products, supported by cutting-edge scientific research and high standards, aimed at laying the foundation for a smoke-free world.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

IQOS Partners with Mexico’s Zamna Festival; PMI Says Adult User Base Tops 140,000
IQOS Partners with Mexico’s Zamna Festival; PMI Says Adult User Base Tops 140,000
Philip Morris International (PMI) said IQOS, via its “IQOS Curious X” platform, has entered a global partnership with the Zamna music festival in Tulum, Mexico, with the collaboration making its on-site debut during Zamna 2026 and targeting adult nicotine users. PMI said IQOS has more than 34 million users worldwide, while the number of adult consumers in Mexico has surpassed 140,000.
Jan.15 by 2FIRSTS.ai
STG UK refreshes XQS nicotine pouch packaging: new flavour indicators, hitting retail from March
STG UK refreshes XQS nicotine pouch packaging: new flavour indicators, hitting retail from March
Scandinavian Tobacco Group UK (STG UK) has announced a rebrand across its XQS nicotine pouch range. The updated packaging will be visible at retail from March, with the recommended retail price remaining £5.50. The new packs feature a bolder logo and glossy textures, retain nicotine strength indicators, and add a side flavour profile indicator to show the flavour type.
Feb.28 by 2FIRSTS.ai
Imperial Brands names John Rishton chair-designate, to take over as chair in December 2026
Imperial Brands names John Rishton chair-designate, to take over as chair in December 2026
Imperial Brands said in a statement on its website that John Rishton will join the board in July 2026 and assume the role of chair in December, succeeding current chair Thérèse Esperdy, who will retire at that time.
Jan.21 by 2FIRSTS.ai
Türkiye’s trade minister: valued at USD 40 million in illicit e-cigarette products seized over five years
Türkiye’s trade minister: valued at USD 40 million in illicit e-cigarette products seized over five years
Türkiye’s Trade Minister Ömer Bolat said that over the past five years, authorities carried out 4,589 operations seizing 28,683,985 e-cigarette devices and parts and 1,070,586 grams/ml of e-liquid, valued at TL 1,762,796,000 (about USD 40,544,308).
Jan.20 by 2FIRSTS.ai
China to Cancel VAT Export Rebates on E-Cigarette Products from April 1, 2026
China to Cancel VAT Export Rebates on E-Cigarette Products from April 1, 2026
China’s Ministry of Finance and State Taxation Administration have announced adjustments to export tax rebate policies, placing nicotine-containing non-combustible inhalation products within the scope of items subject to rebate cancellation. The measures will take effect from April 1, 2026.
Regulations
Jan.10
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11